Tuberculosis vaccine H56IC - Valneva/Statens Serum Institut

Drug Profile

Tuberculosis vaccine H56IC - Valneva/Statens Serum Institut

Alternative Names: Adjuvanted TB subunit vaccine H56IC - Valneva/Statens Serum Institut; AERAS-456; Ag85B-ESAT-6-Rv2660-IC31; H56/AERAS-456 + IC31; H56/IC31 vaccine; H56: IC31; H56IC

Latest Information Update: 04 Aug 2016

Price : $50

At a glance

  • Originator Statens Serum Institut
  • Developer Aeras; Statens Serum Institut
  • Class Adjuvants; Antituberculars; Recombinant fusion proteins; Subunit vaccines; Synthetic vaccines; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Tuberculosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Tuberculosis(Prevention, In volunteers) in Netherlands (IM, Injection)
  • 08 Jul 2016 Phase-II clinical trials in Tuberculosis in South Africa (IM) (Aeras pipeline, July 2016)
  • 01 Nov 2015 Aeras and Statens Serum Institut complete a phase I/II trial in Tuberculosis in South Africa (NCT01865487)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top